These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38157199)

  • 21. Comparison of Botulinum Toxin Injections and Type 2 Thyroplasty for Adductor Spasmodic Dysphonia.
    Sanuki T; Takemoto N
    Laryngoscope; 2023 Dec; 133(12):3443-3448. PubMed ID: 37278482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship of laryngeal botulinum toxin dosage to patient age, vitality, and socioeconomic issues.
    Young DL; Halstead LA
    J Voice; 2014 Sep; 28(5):614-7. PubMed ID: 24954039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative laryngeal electromyography parameters may correlate with improved outcomes following botulinum toxin injection for spasmodic dysphonia.
    Dwyer CD; Leclerc AA; Nandedkar SD; Young VN; Rosen CA
    Muscle Nerve; 2021 Apr; 63(4):525-530. PubMed ID: 33382480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment efficacy of electromyography versus fiberscopy-guided botulinum toxin injection in adductor spasmodic dysphonia patients: a prospective comparative study.
    Kim JW; Park JH; Park KN; Lee SW
    ScientificWorldJournal; 2014; 2014():327928. PubMed ID: 25383369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Botulinum Toxin Therapy for Spasmodic Dysphonia in Japan: The History and an Update.
    Hyodo M; Hirose K; Nagao A; Nakahira M; Kobayashi T
    Toxins (Basel); 2022 Jul; 14(7):. PubMed ID: 35878189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients.
    Rosow DE; Pechman A; Saint-Victor S; Lo K; Lundy DS; Casiano RR
    J Voice; 2015 May; 29(3):352-5. PubMed ID: 25242042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors Associated with Failure of Botulinum Toxin Injection in Adductor Spasmodic Dysphonia.
    Zhao K; Guillaud M; Hu A
    Ann Otol Rhinol Laryngol; 2020 Oct; 129(10):996-1002. PubMed ID: 32468829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality of Life After Botulinum Toxin Injection in Patients With Adductor Spasmodic Dysphonia; a Systematic Review and Meta-analysis.
    Faham M; Ahmadi A; Silverman E; Harouni GG; Dabirmoghaddam P
    J Voice; 2021 Mar; 35(2):271-283. PubMed ID: 31477348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spasmodic dysphonia and botulinum toxin: experience from the largest treatment series.
    Blitzer A
    Eur J Neurol; 2010 Jul; 17 Suppl 1():28-30. PubMed ID: 20590805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Laryngeal Botulinum Toxin Injection: Can It Be a Cause of Obstructive Sleep Apnea as an Adverse Effect?
    Oktay Arslan B; Demirhan E; Uçar Hoşgör ZZ
    J Voice; 2022 Jan; 36(1):119-122. PubMed ID: 32482493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Botulinum toxin. A new therapeutic alternative in spastic dysphonia (laryngeal abductor dystonia)].
    Loven JO; Brøndbo K; Ganes T
    Tidsskr Nor Laegeforen; 1993 Mar; 113(7):841-3. PubMed ID: 8480289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Life Threatening Delayed Complication of Botulinum Toxin Injection for Treatment of Spasmodic Dysphonia.
    Yershov D; Partridge R
    Prague Med Rep; 2020; 121(2):114-117. PubMed ID: 32553095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients.
    Blitzer A; Brin MF; Stewart CF
    Laryngoscope; 1998 Oct; 108(10):1435-41. PubMed ID: 9778279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adductor spasmodic dysphonia: Botulinum toxin a injections or laser thyroarytenoid myoneurectomy? A comparison from the patient perspective.
    Schuering JHC; Heijnen BJ; Sjögren EV; Langeveld APM
    Laryngoscope; 2020 Mar; 130(3):741-746. PubMed ID: 31169922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hemodynamic Changes Associated With Transcervical Laryngeal Injection of Botulinum Toxin.
    Hernandez BO; Nagatsuka M; Wright SC; Marcellino AJ; Lovin BD; Walker FO; Madden LL
    J Voice; 2023 May; 37(3):452-455. PubMed ID: 33541763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Botulinum toxin for the treatment of spasmodic dysphonia.
    Gibbs SR; Blitzer A
    Otolaryngol Clin North Am; 2000 Aug; 33(4):879-94. PubMed ID: 10918666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized controlled trial of belladonna and opiate suppository during intravesical onabotulinum toxin A injection.
    LeClaire EL; Duong J; Wykes RM; Miller KE; Winterton TL; Bimali M
    Am J Obstet Gynecol; 2018 Nov; 219(5):488.e1-488.e7. PubMed ID: 29902447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of an Upper Respiratory Tract Infection on Botulinum Toxin Efficacy in Spasmodic Dysphonia Patients.
    Kirke DN; Kaye R; Blitzer A
    Laryngoscope; 2020 Jul; 130(7):1746-1749. PubMed ID: 31508822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Botulinum Toxin Dosing Trends in Spasmodic Dysphonia Over a 20-year Period.
    Namin AW; Christopher KM; Eisenbeis JF
    J Voice; 2017 Jan; 31(1):107-110. PubMed ID: 27005439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Botulinum toxin injection for abductor spasmodic dysphonia under cervical ultrasonography guidance.
    Kunieda C; Nin F; Ohashi T; Hosokawa K; Watanabe Y; Ogawa T; Mori T; Kanazawa T
    Auris Nasus Larynx; 2024 Apr; 51(2):361-364. PubMed ID: 37838568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.